摘要
目的评价阿昔洛韦滴眼液(正大捷普)和重组人干扰素a-2b滴眼液治疗单纯疱疹性角膜炎(HSK)的临床疗效。方法治疗组HSK62例,69眼,滴用正大捷普和重组干扰素a-2b滴眼液,并静脉滴注阿昔洛韦,对照组HSK41例,43眼,用普通阿昔洛韦滴眼液联合羟苄唑滴眼液并静脉滴注阿昔洛韦,比较两组的治愈率、有效率及复发率。结果治疗组疗效明显优于对照组(P<0.01),治疗组复发率低于对照组。结论临床应用正大捷普联合重组干扰素a-2b滴眼液治疗单纯疱疹性角膜炎能提高疗效,降低复发率,具有较好的治疗和抗复发效果,降低了致盲率。
Objective To evaluate the effect of aciclovir eye drops combined with recombinant human interferon a-2b eye drops in the treatment of herpes simplex keratitis （HSK）. Methods In the treatment group 69 eyes of 62 cases were treated with aciclovir eye drops combined with recombinant human interferon a-2b eye drops, at the same time, intravenous drip of aciclovir, compared with the control group 43 eyes of 41 cases which were treated with ordinary aciclovir eye drops combined with hydrobenzole hydrochloride eye drops as well as intravenous drip of acyclovir. Their cure rate, effective rate and relapse rate were compared. Results The curative effect of the treatment group was superior to that of the control group （P〈0.01） and the relapse rate in 1 year later was obviously low. Conclusion Aciclovir eye drops combined with recombinant human interferon a-2b eye drops for the treatment of HSK can improve efficacy, decrease relapse and blindness.
出处
《食品与药品》
CAS
2007年第05A期17-19,共3页
Food and Drug
